NCT00195689View on ClinicalTrials.gov

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 31, 2003

Conditions
Psoriatic Arthritis
Interventions
BIOLOGICAL

Human anti-TNF monoclonal antibody/adalimumab

Trial Locations (1)

60064

Global Medical Information-Abbott Laboratories, Abbott Park

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY